Featured Research

from universities, journals, and other organizations

Bionic pancreas controls blood sugar levels in adults, adolescents with type 1 diabetes

Date:
June 16, 2014
Source:
Massachusetts General Hospital
Summary:
The latest version of a bionic pancreas device has been successfully tested in two five-day clinical trials -- one in adults, the other in adolescents -- that imposed minimal restrictions on patient activities.

The bionic pancreas developed by a Boston University/Massachusetts General Hospital research team consists of a smartphone (above) hardwired to a continuous glucose monitor and two pumps (below) that deliver doses of insulin or glucagon every five minutes.
Credit: Boston University Department of Biomedical Engineering

The latest version of a bionic pancreas device has been successfully tested in two five-day clinical trials -- one in adults, the other in adolescents -- that imposed minimal restrictions on patient activities. A team of investigators from Boston University (BU) and Massachusetts General Hospital (MGH) report study results in a New England Journal of Medicine paper being issued online to coincide with a presentation at the American Diabetes Association Scientific Sessions. The device controls blood sugar in patients with type 1 diabetes using doses of both insulin and the blood-sugar-raising hormone glucagon.

Related Articles


"In both of these studies this device far exceeded our expectations in terms of its ability to regulate glucose, prevent hypoglycemia and automatically adapt to the very different needs of adults -- some of whom were very insulin-sensitive -- and adolescents, who typically need higher insulin doses," says Edward Damiano, PhD, of the BU Department of Biomedical Engineering, principal investigator of the project and senior author of the NEJM report. "There's no current standard-of-care therapy that could match the results we saw."

Firas El-Khatib, PhD, of the BU Department of Biomedical Engineering, adds, "One of the key virtues of this device is its ability to start controlling the blood sugar instantly, based only on the patient's weight, and continually adapt its decision making regarding insulin and glucagon dosing to handle a wide range of dosing requirements." El-Khatib co-designed the bionic pancreas device with Damiano and is co-lead author of the NEJM report with Steven Russell, MD, PhD, of the MGH Diabetes Unit,.

Russell -- who led the clinical trials reported in the current paper -- Damiano, and El-Khatib previously published a 2010 Science Translational Medicine report that described successful use of the first-generation system in controlling the blood sugar of adults for 27 hours. But that study took place in a controlled hospital inpatient environment where participants essentially stayed in bed for the whole period and ate prescribed meals. "The key element with the current version of this device is that it's wearable, allowing participants to stay in something close to their usual environments, exercise and eat whatever they want," says Russell.

Additional inpatient trials conducted after the 2010 paper extended the study period to two days and included adolescents as well as adults. But developing a device that could be tested safely in an outpatient environment presented several challenges, first among which was a control system that could adapt not only to the minute-by-minute changing needs of an individual, but also to the very different needs of adults and adolescents. The rapid growth and hormonal changes of adolescence produces insulin requirements that are two to three times greater than those of adults of the same body weight, Damiano explains. And even though the dosage needs of adults are more predictable, contracting typical a illness like a cold or upset stomach can dramatically change the need for insulin over a period of days to weeks.

Along with the software improvements that allow the device to adapt to widely varied individual dosage needs, the new version also relies on improved hardware, including a smartphone (iPhone 4S) capable of practical wireless communication with two pumps delivering doses of insulin and glucagon. Every five minutes the smartphone receives a blood sugar reading from an attached continuous glucose monitor, which it uses to calculate and administer a dose of either insulin or glucagon. The smartphone includes an application on which the patient enters information immediately before eating. But instead of the complex calculation patients typically do to estimate their carbohydrate intake, this app only asks whether the meal consumed will be breakfast, lunch, or dinner and whether the carbohydrate content will be typical, larger or smaller than usual.

Both of the studies reported in the NEJM paper compared data reflecting five days on the bionic pancreas system with five days of participants' usual care using their own insulin pumps. The adult trial enrolled 20 participants who lived at home and managed their own care during the usual-care period. While on the bionic pancreas, participants needed to stay within a three-square-mile area of downtown Boston, which enabled constant wireless monitoring of the blood sugar levels by study staff. They were accompanied by a study nurse 24 hours a day and slept in a hotel; but were otherwise free to do as they chose, including exercising at a gym and eating in restaurants.

The adolescent trial enrolled 32 participants, ages 12 to 20, attending a camp for youngsters with type 1 diabetes, who followed the same activity and meal schedule as other campers during both phases of the trial. They were closely monitored by study and camp staff and via wireless monitoring during their time on the bionic pancreas. Participants in both phases of both trials were alerted if blood sugar levels dropped into a range requiring carbohydrate administration, including during nighttime monitoring.

In both studies, the time on the bionic pancreas produced what Russell calls, "two results that almost never go together. Participants' average blood glucose went down while the incidents of low blood sugar also dropped. The fear of hypoglycemia can limit attempts to bring the average blood sugar into the range that dramatically reduces the risk of long-term complications, so it was remarkable that we saw both of these results at once. Both groups had quite good levels in the usual care arms -- averages of 159 for both adults and adolescents -- but the difference while they were on the bionic pancreas was dramatic, with average blood sugar levels of 133 for the adults and 142 for adolescents." Fewer instances of hypoglycemia on the bionic pancreas also reduced the need for carbohydrate doses to raise blood sugar.

Damiano, whose 15-year-old son was diagnosed with type 1 diabetes at the age of 11 months, explains what having a device like this could mean to patients. "The most practical difference would be not having to think about diabetes 24/7, not having to constantly make decisions about things that those of us without type 1 never have to think about. Another real problem that would be relieved is the fear -- fear of going to bed at night and not knowing if your blood sugar level will drop dangerously low while you sleep. Even our study participants, who controlled their blood sugars significantly better than national averages on their usual care, ran high levels overnight but still had significant episodes of hypoglycemia.

"And another extremely frustrating aspect of diabetes that would be completely eliminated by this device is the enormous sense of failure when you stare at that glucose meter and, despite everything you do to control it, your blood sugar is not in or near the normal range," he continues. "But of course you didn't fail; the tools that are available to you failed. The bionic pancreas we are working toward would relieve that sense of failure and provide a bridge to the often-promised but still elusive cure for type 1 diabetes."


Story Source:

The above story is based on materials provided by Massachusetts General Hospital. Note: Materials may be edited for content and length.


Journal Reference:

  1. Steven J. Russell, Firas H. El-Khatib, Manasi Sinha, Kendra L. Magyar, Katherine McKeon, Laura G. Goergen, Courtney Balliro, Mallory A. Hillard, David M. Nathan, Edward R. Damiano. Outpatient Glycemic Control with a Bionic Pancreas in Type 1 Diabetes. New England Journal of Medicine, 2014; 140615180011006 DOI: 10.1056/NEJMoa1314474

Cite This Page:

Massachusetts General Hospital. "Bionic pancreas controls blood sugar levels in adults, adolescents with type 1 diabetes." ScienceDaily. ScienceDaily, 16 June 2014. <www.sciencedaily.com/releases/2014/06/140616093617.htm>.
Massachusetts General Hospital. (2014, June 16). Bionic pancreas controls blood sugar levels in adults, adolescents with type 1 diabetes. ScienceDaily. Retrieved November 28, 2014 from www.sciencedaily.com/releases/2014/06/140616093617.htm
Massachusetts General Hospital. "Bionic pancreas controls blood sugar levels in adults, adolescents with type 1 diabetes." ScienceDaily. www.sciencedaily.com/releases/2014/06/140616093617.htm (accessed November 28, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Friday, November 28, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Rural India's Low-Cost Sanitary Pad Revolution

Rural India's Low-Cost Sanitary Pad Revolution

AFP (Nov. 28, 2014) — One man hopes his invention -– a machine that produces cheap sanitary pads –- will help empower Indian women. Duration: 01:51 Video provided by AFP
Powered by NewsLook.com
Research on Bats Could Help Develop Drugs Against Ebola

Research on Bats Could Help Develop Drugs Against Ebola

AFP (Nov. 28, 2014) — In Africa's only biosafety level 4 laboratory, scientists have been carrying out experiments on bats to understand how virus like Ebola are being transmitted, and how some of them resist to it. Duration: 01:18 Video provided by AFP
Powered by NewsLook.com
Ebola Leaves Orphans Alone in Sierra Leone

Ebola Leaves Orphans Alone in Sierra Leone

AFP (Nov. 27, 2014) — The Ebola epidemic sweeping Sierra Leone is having a profound effect on the country's children, many of whom have been left without any family members to support them. Duration: 01:02 Video provided by AFP
Powered by NewsLook.com
Experimental Ebola Vaccine Shows Promise In Human Trial

Experimental Ebola Vaccine Shows Promise In Human Trial

Newsy (Nov. 27, 2014) — A recent test of a prototype Ebola vaccine generated an immune response to the disease in subjects. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins